FY2024 EPS Estimates for Alumis Reduced by Leerink Partnrs

Alumis Inc. (NASDAQ:ALMS) – Research analysts at Leerink Partnrs reduced their FY2024 earnings per share estimates for shares of Alumis in a report released on Wednesday, November 13th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings of ($9.55) per share for the year, down from their previous forecast of ($8.13). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Alumis’ current full-year earnings is ($7.98) per share. Leerink Partnrs also issued estimates for Alumis’ Q4 2024 earnings at ($1.34) EPS, FY2025 earnings at ($5.19) EPS, FY2026 earnings at ($5.52) EPS, FY2027 earnings at ($6.54) EPS and FY2028 earnings at ($4.04) EPS.

ALMS has been the topic of several other research reports. Baird R W upgraded Alumis to a “strong-buy” rating in a report on Thursday, October 31st. HC Wainwright reduced their target price on shares of Alumis from $30.00 to $26.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. Leerink Partners began coverage on shares of Alumis in a report on Tuesday, July 23rd. They set an “outperform” rating and a $29.00 price target for the company. Guggenheim assumed coverage on Alumis in a report on Tuesday, July 23rd. They issued a “buy” rating and a $32.00 price objective on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a research note on Thursday, November 14th. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Alumis currently has a consensus rating of “Buy” and a consensus target price of $26.83.

Alumis Trading Down 2.4 %

Shares of Alumis stock opened at $8.64 on Monday. The stock’s 50 day moving average is $11.22. Alumis has a one year low of $8.23 and a one year high of $13.53.

Institutional Trading of Alumis

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets acquired a new stake in shares of Alumis in the third quarter valued at $27,000. MetLife Investment Management LLC acquired a new position in Alumis in the 3rd quarter valued at about $89,000. Barclays PLC purchased a new stake in Alumis during the third quarter worth about $197,000. Maven Securities LTD acquired a new stake in shares of Alumis during the second quarter worth about $332,000. Finally, State Street Corp purchased a new position in shares of Alumis in the third quarter valued at approximately $866,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.